New Targeted Alpha Therapy Protocol for Advanced Prostate Cancer

Excerpt:

“Therapy options are limited for men with advanced-stage, metastatic castration-resistant prostate cancer (mCRPC), but a new treatment protocol offers hope. In the featured article of The Journal of Nuclear Medicine‘s October issue, German researchers report on their recent clinical experience, which establishes a dosing regimen for actinium-225 (225Ac)-labeled targeted alpha therapy of patients with prostate specific membrane antigen (PSMA)-positive tumors. The protocol balances treatment response with toxicity concerns to provide the most effective therapy with the least side effects.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Hope for Metastatic Prostate Cancer Patients: Targeted Alpha Therapy Shows Impressive Results

Excerpt:

“Nearly three years of research have brought about remarkable results for the majority of 80 patients subjected to targeted alpha therapy of metastatic prostate cancer. The first assessments — describing a full response in two patients in critical clinical condition with extensive metastases — are published in the December issue of the Journal of Nuclear Medicine (JNM), which has displayed images depicting the improvements on its cover page.

“The tumour has completely disappeared in the two patients after three to four treatments and can no longer be detected neither by PET/CT imaging nor by the tumour marker PSA (Prostate-specific antigen), whose blood level is often elevated in men with prostate cancer. PET/CT (positron emission tomography-computed tomography) is a technique used in oncology that combines the use of two devices to provide a highly accurate picture of the spread of cancer.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.